Loading…
Based on limited metadata, the FDA issued a warning letter to Barox Co., Ltd., a pharmaceutical company, on November 28, 2018. Without access to the full letter text or subject line, the specific nature of the violations cannot be determined from the available information. The warning pertains to drug products under FDA jurisdiction, though the particular issuing office is not specified in the metadata provided. To understand the complete regulatory concerns and required corrective actions, review of the full warning letter text would be necessary.